Supernus Pharmaceuticals (NASDAQ:SUPN) Downgraded to “Buy” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a report released on Saturday morning.

A number of other equities analysts also recently weighed in on SUPN. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Cantor Fitzgerald increased their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Supernus Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $62.83.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $46.20 on Friday. The stock has a fifty day moving average price of $46.48 and a two-hundred day moving average price of $49.24. Supernus Pharmaceuticals has a 52-week low of $32.53 and a 52-week high of $59.68. The company has a market cap of $2.68 billion, a price-to-earnings ratio of -90.59, a PEG ratio of 0.99 and a beta of 0.54.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SUPN. Rubric Capital Management LP acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $21,908,000. Assenagon Asset Management S.A. bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at $27,428,000. Woodline Partners LP raised its stake in Supernus Pharmaceuticals by 63.5% during the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares during the period. SG Americas Securities LLC raised its stake in Supernus Pharmaceuticals by 2,847.0% during the 1st quarter. SG Americas Securities LLC now owns 377,213 shares of the specialty pharmaceutical company’s stock worth $19,498,000 after buying an additional 364,413 shares during the period. Finally, Bank of America Corp DE lifted its holdings in Supernus Pharmaceuticals by 67.1% during the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after acquiring an additional 338,584 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.